Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -0.0%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $163894 | $512481 | $550645 | $960073 | $6M | $5M | — | — | — | — |
| Enterprise Value | $843.2B | $843.2B | $-4994460 | $-5901944 | $-26652927 | $-5907392 | $-4535070 | — | — | — | — |
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.48 | 0.07 | 0.13 | — | 11.78 | 14.31 | 2.82 | — | — | — | — |
| P/B Ratio | 0.00 | 0.00 | 0.10 | 0.10 | 0.04 | 1.26 | 0.54 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 338736.66 | -1.26 | — | -326.93 | -15.32 | -2.49 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 97.6% | — | -11090.9% | 100.0% | 100.0% | 100.0% | -95.1% | -87.6% | -137.8% |
| Operating Margin | -869.3% | -869.3% | -635.8% | — | -17207.5% | -4862.7% | -154.5% | -201.8% | -266.1% | -202.2% | -394.9% |
| Net Profit Margin | -862.3% | -862.3% | -632.0% | — | -17198.3% | -4817.2% | -162.2% | -201.6% | -265.8% | -201.8% | -394.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.0% | -0.0% | -462.3% | -160.5% | -90.6% | -266.6% | -74.0% | — | — | — | -452.8% |
| ROA | -0.0% | -0.0% | -286.6% | -127.8% | -65.0% | -167.4% | -54.5% | -426.8% | -452.2% | -394.4% | -337.0% |
| ROIC | -0.0% | -0.0% | — | — | — | — | — | — | — | — | — |
| ROCE | -0.0% | -0.0% | -465.1% | -165.3% | -85.1% | -235.1% | -70.1% | — | — | — | -453.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | — | — | — | — | 0.02 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.22 | -1.09 | -1.12 | -1.04 | -2.62 | -1.01 | — | — | — | -1.89 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -1168.23 | — | — | -14439.37 | -19.61 | -526.39 | -987.45 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.74 | 2.74 | 2.55 | 2.24 | 6.10 | 2.14 | 12.63 | 0.22 | 0.38 | 0.55 | 1.47 |
| Quick Ratio | 2.74 | 2.74 | 2.55 | 2.24 | 6.10 | 2.15 | 12.63 | 0.22 | 0.46 | 0.55 | 1.47 |
| Cash Ratio | 0.00 | 0.00 | 1.77 | 1.83 | 5.82 | 2.10 | 12.20 | 0.14 | 0.16 | 0.39 | 1.23 |
| Asset Turnover | — | 0.00 | 0.48 | — | 0.00 | 0.03 | 0.18 | 2.51 | 1.50 | 2.19 | 1.36 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 60.86 | — | — | 46.40 | 36.56 | 21.29 | 46.17 | 20.28 | 12.36 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $958443 | $207482 | $101595 | $101595 | $101595 | $101595 | $101595 | $101595 | $101595 | $101595 |
Insufficient liquidity for operations
As reported in recent financial filings, GeoVax trades at a price-to-sales ratio of 0.52, a valuation multiple that suggests the market assigns minimal terminal value to the company's intellectual property portfolio given the absence of commercial revenue and the persistent, heavy reliance on dilutive equity financing.
The current P/S multiple is largely an artifact of sporadic grant-based revenue rather than a reflection of sustainable commercial growth, rendering traditional valuation metrics like P/E or EV/EBITDA effectively meaningless. Investors should monitor whether the market's pricing of the company as a distressed asset persists, as this valuation level may indicate that the market is pricing in a high probability of further equity dilution to fund ongoing clinical trials.
Based on historical financial data, GeoVax has consistently generated deeply negative returns on invested capital, with ROIC figures frequently plummeting into the triple digits, illustrating a structural inability to convert research expenditures into meaningful economic value or sustainable returns for shareholders over the long term.
The extreme volatility in ROIC, including a -9482.8% reading in 2025Q1, highlights the inefficiency of the current capital allocation model where massive R&D outlays fail to produce commercialized assets. This trend suggests that the company is effectively destroying capital rather than compounding it, which warrants further investigation into whether the current pipeline can ever reach a commercial inflection point.
According to quarterly reports, GeoVax exhibits highly erratic efficiency metrics, with days payable outstanding reaching extreme levels such as 8,279 days in 2026Q1, which suggests that the company is managing its limited cash resources by significantly delaying payments to vendors and service providers to maintain operational continuity.
The lack of consistent asset turnover, which has remained below 0.40 in recent periods, confirms that the company's asset base is not being utilized to generate productive output. This inefficiency is a direct consequence of the pre-revenue business model, where the focus remains on clinical development rather than operational throughput or working capital optimization.
As indicated by the most recent quarterly data, the current ratio has compressed to 1.06, signaling that GeoVax's ability to cover short-term obligations is increasingly constrained as cash reserves dwindle to levels that appear insufficient to support long-term clinical development without immediate and significant external capital injections.
The rapid contraction of the current ratio from 3.62 in 2025Q1 to 1.06 in 2026Q1 underscores a deteriorating liquidity position that leaves the company with virtually no margin for error. Investors should monitor the company's cash runway closely, as the current balance sheet suggests that the firm is approaching a point where operational survival is entirely dependent on the timing of future financing rounds.
The most commonly misapplied ratio for GeoVax is the price-to-sales multiple, which obscures the reality that the company's revenue is derived from non-recurring, expense-reimbursement grants rather than commercial product sales, making it a poor proxy for assessing the underlying health or growth potential of the business.
Analysts should instead focus on the cash burn rate and the duration of the operational runway, as these metrics provide a more accurate assessment of the company's viability than revenue-based multiples. Using P/S to value a clinical-stage biotech firm like GeoVax risks misinterpreting grant-funded research activity as a sign of commercial traction, which is fundamentally misleading given the company's current lack of a marketable product.
Includes 30+ ratios · 29 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GOVX stock.
GeoVax Labs, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
GeoVax Labs, Inc.'s return on equity (ROE) is -0.0%. The historical average is -169.9%.
Based on historical data, GeoVax Labs, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
GeoVax Labs, Inc. has 100.0% gross margin and -869.3% operating margin.